Research Compound Overview

CJC-1295 + Ipamorelin: Dual-Pathway Growth Hormone Secretagogue Research

Last updated: March 31, 2026

CJC-1295 and Ipamorelin represent the two major pharmacological approaches to stimulating growth hormone (GH) release from the pituitary gland. CJC-1295 is a modified analogue of GHRH (Growth Hormone-Releasing Hormone), acting on GHRH receptors. Ipamorelin is a selective growth hormone secretagogue acting on the ghrelin receptor (GHS-R1a). Together, they target two separate receptor systems that converge on the same GH-releasing machinery, producing an additive effect documented in published research.

This combination is the most widely studied GH secretagogue pairing in neuroendocrine research. Its appeal lies in the selectivity of both compounds — CJC-1295 maintains pulsatile GH release patterns, and Ipamorelin demonstrates minimal cortisol, prolactin, or ACTH elevation compared to earlier-generation secretagogues.

CJC-1295: The GHRH Pathway

CJC-1295 is a synthetic modification of GHRH(1-29), the first 29 amino acids of natural Growth Hormone-Releasing Hormone. The modifications include amino acid substitutions at positions 2, 8, 15, and 27 that dramatically increase resistance to enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV). This extends the compound's biological half-life from the minutes typical of native GHRH to several hours.

The mechanism is straightforward: CJC-1295 binds to GHRH receptors on somatotroph cells in the anterior pituitary gland and stimulates GH synthesis and secretion. What makes it valuable as a research tool is that the GH release it stimulates remains pulsatile — it comes in discrete bursts that mirror the body's natural GH secretion pattern rather than producing a continuous, unphysiological elevation.

A study published in the Journal of Clinical Endocrinology and Metabolism (2006) confirmed that pulsatile GH secretion persists even during continuous CJC-1295 stimulation, establishing that the compound amplifies existing pulsatile patterns rather than overriding them.

Ipamorelin: The Ghrelin Pathway

Ipamorelin is a pentapeptide growth hormone secretagogue that acts on the GHS-R1a receptor — the same receptor activated by ghrelin, the endogenous "hunger hormone." However, Ipamorelin's significance lies in what it does not do: unlike earlier GH secretagogues (GHRP-2, GHRP-6, hexarelin), Ipamorelin demonstrates remarkably selective GH release without significant stimulation of cortisol, ACTH, or prolactin.

This selectivity was documented in the compound's characterization study published in the European Journal of Endocrinology (1998), which identified Ipamorelin as "the first selective growth hormone secretagogue." Earlier compounds in this class stimulated multiple pituitary hormone axes simultaneously, producing unwanted effects that complicated research interpretation. Ipamorelin's clean profile makes it a more precise research tool for studying GH-specific effects.

The Additive Effect: Why Combine Them

GHRH receptors and GHS-R1a receptors represent two independent input signals to the same pituitary somatotroph cells. Published research consistently demonstrates that stimulating both pathways simultaneously produces GH release greater than either pathway alone — an additive effect at the cellular level.

The biological logic: GHRH (CJC-1295's target) drives GH gene transcription and GH synthesis. Ghrelin pathway stimulation (Ipamorelin's target) primarily promotes GH vesicle release from somatotrophs that have already synthesized GH. By increasing both the production of GH and the efficiency of its release, the combination achieves higher GH amplitude while maintaining the pulsatile pattern and selectivity profile of each individual compound.

Research Applications

The combination is used in research examining body composition changes under GH influence, IGF-1 axis dynamics, sleep-associated GH secretion patterns, age-related GH decline (somatopause), and the downstream effects of pulsatile versus continuous GH exposure on target tissues including muscle, bone, and adipose tissue.

Comparison with Tesamorelin

Tesamorelin, another GHRH analogue in the NST catalog, differs from CJC-1295 primarily in its clinical development history — Tesamorelin has FDA approval for a specific clinical indication and extensive human trial data. CJC-1295 has a larger body of preclinical research but a different clinical development trajectory. Both target GHRH receptors, but their structural modifications and pharmacokinetic profiles differ. Researchers selecting between them should consider the specific parameters of their research protocol.

Research Limitations

While both CJC-1295 and Ipamorelin have published human pharmacokinetic and pharmacodynamic data, large-scale clinical trials for specific indications have not been completed for the combination. The optimal timing, ratio, and duration of combined administration for specific research endpoints remain areas of active investigation. Researchers should note that CJC-1295 exists in two forms in the literature — with and without DAC (Drug Affinity Complex) — which have significantly different half-lives and pharmacokinetic profiles.